Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does TOFACITINIB Cause Intentional dose omission? 845 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 845 reports of Intentional dose omission have been filed in association with TOFACITINIB (XELJANZ XR). This represents 0.5% of all adverse event reports for TOFACITINIB.

845
Reports of Intentional dose omission with TOFACITINIB
0.5%
of all TOFACITINIB reports
5
Deaths
86
Hospitalizations

How Dangerous Is Intentional dose omission From TOFACITINIB?

Of the 845 reports, 5 (0.6%) resulted in death, 86 (10.2%) required hospitalization, and 6 (0.7%) were considered life-threatening.

Is Intentional dose omission Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for TOFACITINIB. However, 845 reports have been filed with the FAERS database.

What Other Side Effects Does TOFACITINIB Cause?

Drug ineffective (30,382) Pain (21,659) Condition aggravated (16,925) Arthralgia (15,640) Fatigue (13,551) Rheumatoid arthritis (12,277) Off label use (11,736) Headache (11,061) Joint swelling (10,686) Malaise (9,040)

What Other Drugs Cause Intentional dose omission?

DUPILUMAB (2,269) CERTOLIZUMAB PEGOL (1,253) ADALIMUMAB (845) INFLIXIMAB (815) ABALOPARATIDE (623) ETANERCEPT (615) AMBRISENTAN (595) SODIUM OXYBATE (580) CALCIUM OXYBATE\MAGNESIUM OXYBATE\POTASSIUM OXYBATE\SODIUM OXYBATE (518) SOFOSBUVIR\VELPATASVIR (474)

Which TOFACITINIB Alternatives Have Lower Intentional dose omission Risk?

TOFACITINIB vs TOFERSEN TOFACITINIB vs TOLNAFTATE TOFACITINIB vs TOLODODEKIN ALFA TOFACITINIB vs TOLTERODINE TOFACITINIB vs TOLVAPTAN

Related Pages

TOFACITINIB Full Profile All Intentional dose omission Reports All Drugs Causing Intentional dose omission TOFACITINIB Demographics